{"nctId":"NCT00837577","briefTitle":"MK0431/ONO-5435 Phase III Clinical Trial -Add-on to Voglibose Study for Patients With Type 2 Diabetes Mellitus (MK0431-104)","startDateStruct":{"date":"2009-02-05","type":"ACTUAL"},"conditions":["Diabetes Mellitus, Non-Insulin-Dependent"],"count":133,"armGroups":[{"label":"Sitagliptin/Sitagliptin","type":"EXPERIMENTAL","interventionNames":["Drug: Sitagliptin","Drug: Voglibose"]},{"label":"Placebo/Sitagliptin","type":"EXPERIMENTAL","interventionNames":["Drug: Comparator: Placebo","Drug: Sitagliptin","Drug: Voglibose"]}],"interventions":[{"name":"Comparator: Placebo","otherNames":[]},{"name":"Sitagliptin","otherNames":["Januvia","MK0431","ONO-5435"]},{"name":"Voglibose","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Japanese Patients With Type 2 Diabetes Mellitus, Who Have Inadequate Glycemic Control On Diet/Exercise Therapy And Voglibose Monotherapy\n\nExclusion Criteria:\n\n* Patients Have A History Of Type 1 Diabetes Mellitus","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Hemoglobin A1c (HbA1c) at Week 12","description":"Change from baseline measurement, where the baseline measurement was obtained at randomization (Week 0) before receiving study medication. This study used Japan Diabetes Society (JDS)-certified HbA1c values, the standard at the time when the study was conducted (HbA1c \\[National Glycohemoglobin Standardization Program; NGSP\\] = HbA1c (JDS-HbA1c \\[%\\]) + 0.4%).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.76","spread":"0.42"},{"groupId":"OG001","value":"0.16","spread":"0.64"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 2-hour Postprandial Glucose at Week 12","description":"Change from baseline measurement, where the baseline measurement was obtained at randomization (Week 0) before receiving study medication.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-55.3","spread":"37.9"},{"groupId":"OG001","value":"-4.0","spread":"38.7"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12","description":"Change from baseline measurement, where the baseline measurement was obtained at randomization (Week 0) before receiving study medication.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-22.6","spread":"27.1"},{"groupId":"OG001","value":"-0.1","spread":"22.2"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":70},"commonTop":["Nasopharyngitis","Back Pain","Blood Triglycerides Increased"]}}}